Case Challenges in Clinical Use of PCSK9 Inhibitors
CardiologyPCSK9 Inhibitor in Practice: Real-World Challenges and Solutions
0.5 AMA PRA Category 1 Credit(s) ™
February 07, 2019
The accreditation for this activity has expired.
Primary Audience:
Cardiologists
Relevant Terms:
PCSK9 inhibitors; non-statin therapy; LDL-C; lipid-lowering therapy; hypercholesterolemia
Christopher Paul Cannon, MD
Christopher Paul Cannon, MD
Cardiovascular Division, Brigham and Women's Hospital
Professor of Medicine, Harvard Medical School
Boston, MA
Dr. Cannon is a senior investigator in the Thrombolysis in Myocardial Infarction (TIMI) Study Group, leading trials such as TACTICS-TIMI 18, PROVE IT-TIMI 22, and CLARITY-TIMI 28. He earned his MD from Columbia University College of Physicians and Surgeons in New York, and after completing his residency in internal medicine at Columbia Presbyterian Medical Center, he was a cardiovascular fellow at Brigham and Women's Hospital.P. Barton Duell, MD, FNLA, FAHA
P. Barton Duell, MD, FNLA, FAHA
Director, Lipid Disorders Clinic and LDL Apheresis
Director, Lipid-Atherosclerosis Laboratory
Knight Cardiovascular Institute
Division of Endocrinology, Diabetes, and Clinical Nutrition
Oregon Health and Science University
Portland, Oregon
Dr. Duell’s special areas of interest include lipid disorders (e.g. high cholesterol), metabolic disorders, homocysteine metabolism, prevention of atherosclerosis (heart disease), diabetes, endocrinology and management of obesity. He currently serves as the director of OHSU’s Metabolic Disorders Clinic. He received his medical degree from OHSU in 1983, and completed his medicine residency at OHSU and the University of Chicago. He completed his metabolism, endocrinology and nutrition fellowship at the University of Washington in Seattle.
Michael D. Shapiro, DO, FACC, FSCCT
Michael D. Shapiro, DO, FACC, FSCCT
Associate Professor of Medicine and Radiology
Knight Cardiovascular Institute - Center For Preventive Cardiology
Oregon Health & Science University
Portland, OR
Dr. Shapiro is currently an Assistant Professor of Medicine and Radiology at Oregon Health & Science University where he is on faculty in the Knight Cardiovascular Institute. After completing a cardiology fellowship, Michael spent two additional years in a clinical and research fellowship focused on advanced cardiovascular imaging at Massachusetts General Hospital. At OHSU, he's been able to combine his interests in atherosclerosis imaging and lipidology. Dr. Shapiro’s clinical practice is dedicated to the evaluation and management of patients with lipid and lipoprotein disorders.
Michael has performed extensive research in the field of atherosclerosis imaging and has published widely in that area. He serves on the editorial board for the Journal of Clinical Lipidology and as associate editor for the Journal of Cardiovascular Computed Tomography. Michael is a member of numerous boards and national committees and is frequently invited to speak at national and international meetings on topics related to cardiovascular imaging and prevention of heart disease.
| 1. | Review the latest clinical trial data on PCSK9 inhibitors in reducing cardiovascular events in patients with hypercholesterolemia. | 2. | Discuss the optimal LDL-C goal for patients with hypercholesterolemia at increased risk for cardiovascular events. |
| 3. | Select appropriate patients for nonstatin lipid-lowering therapy. | 4. | Recognize common reasons for PCSK9 inhibitor denial and implement a team-based approach to improve patient access. |
| 1. | Review the latest clinical trial data on PCSK9 inhibitors in reducing cardiovascular events in patients with hypercholesterolemia. |
| 2. | Discuss the optimal LDL-C goal for patients with hypercholesterolemia at increased risk for cardiovascular events. |
| 3. | Select appropriate patients for nonstatin lipid-lowering therapy. |
| 4. | Recognize common reasons for PCSK9 inhibitor denial and implement a team-based approach to improve patient access. |
This CME activity will target Lipidologists, Cardiologists, Endocrinologists, Primary Care Providers (MDs/DOs), Nurse Practitioners (NPs), Physician Assistants (PAs), other healthcare providers who practice in a primary care setting.
ACCREDITATION STATEMENT
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the providership of Horizon CME. Horizon CME is accredited by the ACCME to provide continuing medical education for physicians.
CREDIT DESIGNATION
Horizon CME designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- Read the learning objectives and faculty disclosures.
- Participate in the activity.
- Complete the post-test and activity evaluation.
- Physicians who successfully complete the post-test and evaluation will receive CME credit. You must score 75% or higher on the post-test to receive credit for this activity.
- All other participants who successfully complete the post-test and evaluation will receive a certificate of participation.
- Statement of credit will be available to print from your user history page.
LEARNER ASSURANCE STATEMENT
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.
Dr. Duell has served on Advisory Boards for Akcea, Esperion, Sanofi, Kastle, and RegenxBio. Oregon Health and Science University has received grant funding for contracted research from Esperion, Regeneron and Retrophin.
Additional non-faculty contributors and others involved in the planning, development, and editing/review of the content have no relevant financial relationships to disclose.
DISCLOSURE OF UNLABELED USE
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer's product information, and comparison with recommendations of other authorities.
This activity is supported by an independent educational grant from Sanofi US and Regeneron Pharmaceuticals.
COURSE VIEWING REQUIREMENTS
| Supported Browsers: Internet Explorer 8.0+ for Windows 2000, 2003, Vista, XP, Windows 7, Windows 8 Google Chrome 28.0+ for Windows, Mac OS, or Linux Mozilla Firefox 23.0+ for Windows, Mac OS, or Linux Safari 6+ for Mac OSX 10.7 and above For video playback, install the latest version of Flash or Quicktime. | Supported Phones & Tablets: Android 4.0.3 and above iPhone/iPad with iOS 6.1 or above |
